Abstract

Biosimilars have the potential to improve access to effective therapies by lowering costs, but their demand is regulated by physicians.

Physicians express reservations regarding biosimilar safety, efficacy, and immunogenicity, and may require additional evidence to prescribe biosimilars.

Real-world evidence studies can address evidence gaps and convince all stakeholders, including physicians, about longterm biosimilar use in specific populations.